 |
Coagulation Factor VIIa (Recombinant) |
|---|---|
| Trade Name | Novoseven |
| Orphan Indication | Bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX |
| USA Market Approval | USA |
| USA Designation Date | 2004-07-16 00:00:00 |
| Sponsor | Novo Nordisk, Inc.;100 College Road West;Princeton, New Jersey, 08540 |
